NEW YORK (GenomeWeb News) – Laboratory Corporation of America division Esoterix Clinical Trial Services today announced a deal with the David H. Murdock Research Institute for assay development.
As part of the deal, assays developed at DHMRI will be transferred to LabCorp Clinical Trials laboratories worldwide to support global clinical studies. The agreement also provides for the downstream commercialization of companion diagnostics and other biomarker assays upon clinical validation, Esoterix said.
The deal provides LabCorp's clinical trials clients "the most complete suite of biomarker development tools in the industry," David Johnston, senior vice president and global head of clinical trials for LabCorp, said in a statement.
Services available to LabCorp's clients through the DHMRI include biomarker discovery and proof-of-concept assay develop for early- and late-stage drug discovery and development.
Financial and other terms of the deal were not disclosed.